ANSTO’s OPAL reactor at Lucas Heights in southern Sydney has reached its 20th anniversary since it first achieved criticality on 12 August 2006, marking two decades of service as Australia’s sole multi-purpose research reactor and a key supplier of products and capabilities used across medicine, research and industry.
What OPAL is and why criticality matters
OPAL is a multi-purpose research reactor. In plain terms, the reactor produces a controlled chain reaction that sustains a neutron flux used for scientific experiments, production of medical radioisotopes and testing materials for industrial applications. The moment of first criticality — when a nuclear chain reaction becomes self-sustaining — is the defining step that moves a facility from construction to operational capability. OPAL reached that milestone on 12 August 2006.
Contributions to health, science and industry
According to ANSTO, OPAL has delivered benefits to hospitals, universities, industry and communities across Australia in the 20 years since first criticality. The reactor is central to the production of nuclear medicines used in diagnostic imaging and therapeutic procedures. ANSTO’s chief executive, Shaun Jenkinson, highlighted the ubiquity of nuclear medicine in modern healthcare:
“Every Australian will, on average, require two nuclear medicine procedures in their lifetime. If you or a loved one has undergone a diagnostic imaging scan such as a SPECT scan, it is highly likely the nuclear medicine administered came from Lucas Heights.”
The organisation also points to broader industrial and research impacts: OPAL supports experimental work that helps develop new technologies and quality-control testing for components used in advanced transport and energy systems, among other applications.
- Medical supply: OPAL is a principal source of medical radioisotopes used in diagnostic imaging and treatments.
- Research capability: The reactor provides neutron beams and irradiation facilities for universities and research institutes.
- Industrial support: Materials testing and applied research for industry are enabled by OPAL’s neutron capabilities.
International standing and continuity
ANSTO describes OPAL as one of the world’s most advanced multi-purpose research reactors. That standing arises from the reactor’s design, the ancillary laboratory infrastructure at Lucas Heights and the continuity of operation required to supply time-sensitive medical isotopes. The facility’s combination of research and production roles means it plays both a scientific and an operational role in national healthcare and industrial systems.
ANSTO’s public statements mark the anniversary as an opportunity to reflect on the reactor’s long-term contributions and on the continuing need to maintain reliable production and research capacity. The organisation says OPAL’s work touches everyday life in ways that many people do not directly see, from scans in hospital imaging departments to components in advanced transport systems.
Looking ahead
Two decades of operation underline the importance of sustained investment in nuclear-science infrastructure where reactors provide unique capabilities not easily replicated by other technologies. For countries that rely on reactor-produced isotopes, continuity of supply is a critical issue; research reactors such as OPAL bridge fundamental research, applied science and commercial production.
| Milestone | Date |
|---|---|
| First criticality | 12 August 2006 |
| 20-year anniversary | 2026 |
As the reactor marks 20 years of operation, its record illustrates how a single piece of scientific infrastructure can have ripple effects across healthcare, science and industry. While the technical details of reactor operation are specialised, the practical outcomes — diagnostic scans, material testing and scientific experiments — have everyday relevance.
For nations considering investments in nuclear-science capability, OPAL’s anniversary offers a case study in how research reactors can provide enduring national benefits when paired with stable operational management and integrated research and production programmes.
